E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Heart failure with preserved ejection fraction |
Insuficiencia cardíaca con fracción de eyección preservada |
|
E.1.1.1 | Medical condition in easily understood language |
Heart failure |
Insuficiencia cardíaca |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10069211 |
E.1.2 | Term | Diastolic heart failure |
E.1.2 | System Organ Class | 100000004849 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10019279 |
E.1.2 | Term | Heart failure |
E.1.2 | System Organ Class | 100000004849 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to compare LCZ696 to valsartan in reducing the rate of the composite endpoint of cardiovascular death and total (first and recurrent) heart failure (HF) hospitalizations, in HF patients (NYHA Class II-IV) with preserved EF (LVEF ?45%). The treatment arm with the lower rate of events will be deemed as having a successful response. |
El objetivo principal de este estudio es comparar LCZ696 con valsartan en la reducción de la tasa de la variable compuesta de muerte CV y hospitalizaciones totales (primera y recurrentes) por IC en pacientes con IC (Clase II-IV NYHA) con FE preservada (FE ventricular izquierda [FEVI] ?45%). |
|
E.2.2 | Secondary objectives of the trial |
- Evaluation of the composite endpoint of CV death, total HF hospitalizations, total strokes, and total MIs. The treatment arm with the lower rate of events will be deemed a successful response. - Evaluation of change from baseline to Month 8 in NYHA functional class, a well established grading scale used to classify a HF patients' level of functionality based on the signs and symptoms of HF exhibited by the patient. - Evaluation of the time to onset of atrial fibrillation (AF) in patients wtihout prior AF (no prior history of AF and no AF at baseline). - Evaluation of the time to all cause death. |
? Comparar LCZ696 con valsartan para reducir la tasa de la variable compuesta de muerte CV, hospitalizaciones totales por IC, ictus totales no mortales, e infartos de miocardio (IMs) totales no mortales. Total se define como primero y todos los acontecimientos recurrentes. ? Comparar LCZ696 con valsartan para mejorar la clasificación funcional NYHA a los 8 meses. ? Comparar LCZ696 con valsartan en retrasar el tiempo hasta un nuevo inicio de FA (FANI) en pacientes sin antecedentes de FA y sin FA en el electrocardiograma (ECG) a nivel basal. ? Comparar LCZ696 a valsartan en retrasar el tiempo hasta mortalidad por cualquier causa. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Following substudies are part of main protocol: - To compare LCZ696 to valsartan on the profile of pre-specified biomarkers from baseline to predefined time points in a subset of patients. - To characterize LCZ696 and valsartan pharmacokinetics (PK) at steady-state using population modeling and/or non-compartmental based methods in a subset of patients. - To compare LCZ696 to valsartan in reducing subclinical atrial fibrillation (AF) or AF burden in a subset of patients with no history of AF and without AF on ECG at baseline. |
Los siguientes subestudios son aprte del protocolo principal:? Comparar LCZ696 con valsartan en el perfil de biomarcadores pre-especificados desde la basal a tiempos predefinidos en un subgrupo de pacientes. ? Caracterizar la farmacocinética (PK) de LCZ696 y valsartan en la fase de equilibrio utilizando modelos poblacionales y/o métodos no compartimentales en un subgrupo de pacientes. ? Comparar LCZ696 con valsartan en la reducción de la FA subclínica o la carga de FA en un subgrupo de pacientes sin antecedentes de FA y sin FA en el ECG a nivel basal. |
|
E.3 | Principal inclusion criteria |
- Left ventricular ejection fraction (LVEF) ?45% prior to study entry. - Symptom(s) of heart failure (HF) and requiring treatment with diuretic(s) for HF ?30 days prior to study entry. - Current symptom(s) of HF. - Structural heart disease (left atrial enlargement or left ventricular hypertrophy) documented by echocardiogram. - At least one of the following: a HF hospitalization within 9 months prior to study entry and/or an elevated NT-proBNP. - Other protocol-defined inclusion criteria may apply. |
-FEVI ? 45% antes de Visita 1 -Síntoma(s) de IC que precisa(n) tratamiento con diurético(s) para IC ? 30 días antes de la Visita 1 -Síntoma(s) actual(es) de IC -Enfermedad cardiaca estructural evidenciada por uno o ambos de los siguientes hallazgos de eco . -Pacientes con al menos uno de los siguientes: una hospitalización por IC ( en los 9 meses previos a la Visita 1 y/o . NT-proBNP elevado en la Visita 1 |
|
E.4 | Principal exclusion criteria |
- Any prior measurement of LVEF < 45%. - Acute coronary syndrome (including myocardial infarction (MI)), cardiac surgery, other major cardiovascular surgery within 3 months, or urgent percutaneous coronary intervention (PCI) within 30 days of entry. - Patients who have had an MI, coronary artery bypass graft (CABG) or other event within the 6 months prior to entry unless an echo measurement performed after the event confirms a LVEF ?45%. - Current acute decompensated HF requiring therapy. - Patients who require treatment with 2 or more of the following: an angiotensin converting enzyme inhibitor (ACEI), an angiotensin receptor blocker (ARB) or a renin inhibitor. - Alternative reason for shortness of breath such as: significant pulmonary disease or severe COPD, hemoglobin (Hgb) <10 g/dl, or body mass index (BMI) > 40 kg/m2. - Systolic blood pressure (SBP) ? 180 mmHg at entry, or SBP >150 mmHg and <180 mmHg at entry unless the patient is receiving 3 or more antihypertensive drugs. - Other protocol-defined exclusion criteria may apply. |
1. Cualquier determinación eco previa de FEVI < 45%. 2. Síndrome coronario agudo (incluyendo IM), cirugía cardiaca, otra cirugía CV mayor, o intervención coronaria percutánea (ICP) en los 3 meses previos a la Visita 1 o una ICP de elección en los 30 días antes de la Visita 1. 3. Pacientes que han tenido un IM, derivación aorto coronaria por injerto (CABG) u otro acontecimiento en los 6 meses previos a la Visita 1 que podrían haber reducido su FE a menos que una determinación de eco realizada después del acontecimiento confirme un FEVI ? 45%. 4. IC descompensada aguda actual que precisa terapia aumentada con diuréticos, vasodilatadores y/o fármacos inotrópicos. 5. Pacientes que precisan tratamiento con 2 o más de los siguientes: un IECA, un ARAII o un inhibidor de la renina. 6. Antecedentes de hipersensibilidad a alguno de los fármacos del estudio o a fármacos de clases químicas similares. 7. Pacientes con antecedentes conocidos de angioedema.
10. Pacientes con alguno de los siguientes: a. presión arterial sistólica (PAS) ? 180 mmHg en la Visita 1, o b. PAS >150 mmHg y < 180 mmHg en la Visita 1 a menos que el paciente esté recibiendo 3 o más fármacos antihipertensivos. Fármacos antihipertensivos incluyen, pero sin limitarse a, una tiazida u otro diurético, antagonistas mineralocorticosteroides (ARM), IECA, ARAII, beta bloqueantes y bloqueantes del canal del calcio (BCC), o c. PAS < 110 mmHg en la Visita 1, o d. PAS < 105 mmHg hipotensión sintomática determinada por el investigador en la Visita 103 o Visita 201 VEr otros criterios en el protocolo |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Cumulative number of primary composite events of cardiovascular (CV) death and total (first and recurrent) HF hospitalizations. |
La variable de eficacia principal del estudio consiste en los tiempos hasta hospitalización recurrente por insuficiencia cardiaca y tiempo de muerte por CV durante el seguimiento del paciente |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Total follow up time (up to 57 months) |
hasta 57 meses |
|
E.5.2 | Secondary end point(s) |
- Cumulative number of events of the extended composite endpoint of CV death, total HF hospitalizations, total non-fatal strokes, and total non-fatal myocardial infarctions (MIs). - Change from baseline to Month 8 in New York Heart Association (NYHA) functional class. - Time to new onset of atrial fibrillation (AF). - Time to all-cause mortality. |
? El número acumulativo de acontecimientos de la variable compuesta ampliada de muerte CV, total de hospitalizaciones por IC no mortales, total de ictus no mortales, y total de IMs no mortales, a lo largo del tiempo durante el periodo doble ciego del estudio ? Cambio en la clase NYHA desde la basal al Mes 8 ? Tiempo hasta nuevo inicio de FA ? Tiempo hasta mortalidad por cualquier causa |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- Total follow up time (up to 57 months). - 8 months for the NYHA functional class. |
-Hasta 57 meses -8 meses para la clase funcional NYHA |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 25 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 321 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Bulgaria |
Canada |
China |
Denmark |
France |
Greece |
Italy |
Austria |
Croatia |
Netherlands |
Norway |
Portugal |
Romania |
Slovakia |
Sweden |
Dominican Republic |
Argentina |
Brazil |
Chile |
Colombia |
Czech Republic |
Ecuador |
Finland |
Germany |
Guatemala |
Hong Kong |
Hungary |
Korea, Republic of |
Spain |
Israel |
Mexico |
Panama |
Peru |
Philippines |
Russian Federation |
Serbia |
Singapore |
South Africa |
Switzerland |
Taiwan |
Turkey |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS (15-Aug-2018) |
ültima visita del último paciente incluido (15 Agosto 2013 |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |